Figures & data
Table 1. Effect of intravaginal administration of LFNPs on body and organ weights (gm).
Table 2. Bioavailability of drugs (µg/ml) in the vaginal lavage of rats that received drug loaded LFNPs by intravaginal route.
Table 3. Bioavailability of drugs in the blood (ng/ml) of rats that received drug loaded LFNPs by intravaginal route.
Figure 1. Histopathology of vagina after vaginal administration of DL-LFNPs. Rats were administered 30 mg of DL-LFNPs via the vaginal route for 20 days. At the end of the treatment, vaginal tissue was collected, sectioned and stained with hematoxylin and eosin.
Table 4. Effect of vaginal administration of drug-loaded LNPs on the progress of pregnancy and development of pups.
Table 5. Effect of oral administration of LFNPs on body and organ weights (gm).
Table 6. Effect of oral administration of LFNPs on sperm count and fertility.
Figure 2. Histopathology of reproductive tissues after oral administration of DL-LFNPs. Male wistar rats were administered 5 mg/Kg of DL-LFNPs for 3 weeks. Following treatment, caput, cauda and testis were collected, sectioned and stained with hematoxylin and eosin.
Table 7. Effect of oral administration of drug-loaded LNPs on the progress of pregnancy and development of pups.